VEST: The UK Vedolizumab Real Life Experience Study in Inflammatory Bowel Disease

University Hospital Southampton NHS Foundation Trust

Status: Unknown

Conditions: Ulcerative Colitis; Crohn's Disease

Study type: Observational

Funder types: Other

Identifiers

NCT03257345

RHM MED1307

Details and patient eligibility

About

Vedolizumab has been approved for the treatment of both ulcerative colitis and Crohn's disease. The aim of this study is to capture the early real life UK experience of vedolizumab including the outcomes of treatment, describing the patient population treated, drug persistence, IBD control PROM, durable remission, tolerance and safety.

Enrollment: 360 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants being given vedolizumab as part of routine care, and vedo naïve prior to study
• Age 18 or over
• Written informed consent obtained from patient for participation in the UK IBD Registry

Exclusion criteria

• Patient unwilling to take part in the UK IBD Registry
• Unable to obtain written informed consent
• Patient is, in the opinion of the investigator, not suitable to participate in the study
• Patients with contraindications to the use of vedolizumab